Clinical trials: VTE Prophylaxis
- Condition VTE Prophylaxis
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Venous Thromboembolism
A Study in Europe Based on Medical Records That Looks at the Safety of Dabigatran in Children Below 2 Years of Age Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot
The study is designed to collect and evaluate Dabigatran Etexilate (DE) safety in the context of routine anticoagulation care provided in the European Union (EU)/European Economic Area (EEA) for children under 2 years of age.
- Trial name
- DaPaR (NCT05536791)
- Testing
- Dabigatran Etexilate (DE)
- Where
- 6 sites in Germany, Netherlands and 2 more
- Sponsor
- Boehringer Ingelheim
VTE Prophylaxis
Study Evaluating Betrixaban in Pediatric Participants
This trial was a Phase 1, open-label, multicenter study of the pharmacokinetics (PK), pharmacodynamics (PD), and safety of a single dose of betrixaban in pediatric participants at risk of venous thromboembolism (VTE).
- Trial name
- NCT03346083
- Testing
- Betrixaban
- Where
- 20 sites in United States, Russia and 2 more
- Volunteers
- 21 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Venous Thromboembolism (VTE)
Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC)
This study is researching 2 different experimental drugs called REGN7508 and REGN9933 (called "study drugs"). The study is focused on people who have a tube placed in a vein to receive treatment (called Peripherally Inserted…
- Trial name
- ROXI-PEAK (NCT07697599)
- Testing
- REGN7508, REGN9933
- Where
- Georgia
- Volunteers
- 1,908 people
- Sponsor
- Regeneron Pharmaceuticals
Venous Thromboembolism
ELIQUIS (APIXABAN) Regulatory Post-Marketing Surveillance In Clinical Practice for Venous Thromboembolism (VTE) Treatment and Prevention Of Recurrent VTE
The primary objectives of this study is to estimate the real-world safety profile of Eliquis in Japanese Venous Thromboembolism patients and to estimate the risk factors likely to affect the incidence of bleeding.
- Trial name
- NCT02836457
- Where
- Japan
- Volunteers
- 1,134 people
- Sponsor
- Bristol-Myers Squibb